IGC Pharma, Inc. (IGC) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025, and the six months ended on that date. IGC Pharma, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for Alzheimer's Disease (AD) and related disorders using Artificial Intelligence (AI). The company's lead candidate, IGC-AD1, is in Phase 2 clinical development for agitation in Alzheimer's dementia. The company operates as a single reportable segment: Life Sciences.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2025 | Six Months Ended Sept 30, 2025 | Balance Sheet (Sept 30, 2025) |
|---|---|---|---|
| Revenue | $191 | $519 | - |
| Net Loss | $(1,821) | $(3,420) | - |
| Operating Loss | $(2,899) | $(4,804) | - |
| Cash and Cash Equivalents | - | - | $1,105 |
| Working Capital | - | - | $490 |
| Long-Term Debt | - | - | $132 |
| Stockholders' Equity | - | - | $8,092 |
Note: Revenue is derived primarily from white-label services ($153k for Q2) and wellness/lifestyle products ($38k for Q2). Gross margin for the quarter was approximately 52%.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 54% year-over-year for the quarter (from $412k to $191k) and 24% for the six-month period. Management attributes this to a strategic shift toward clinical trials and the transition of manufacturing operations following the sale of the Vancouver facility.
- Expense Increases: R&D expenses increased 73% year-over-year for the quarter ($1.6M vs $0.9M) due to the progression of Phase 2 trials for IGC-AD1. SG&A expenses increased 35% for the quarter ($1.4M vs $1.0M) due to marketing and corporate expenses.
- Other Income Surge: "Other income, net" increased significantly to $1.1M for the quarter (from $43k) and $1.4M for the six months (from $61k). This is primarily driven by a recognized gain of approximately $1.2M from the disposition of assets (Vancouver facility).
- Liquidity Improvement: Cash and cash equivalents increased by 173% to $1.1M compared to the prior fiscal year-end, driven by financing activities and asset sales.
Guidance, Outlook, and Risks
- Clinical Milestones: The company successfully enrolled over 50% of patients in its Phase 2 CALMA trial for IGC-AD1. The trial was expanded to new international sites in Canada and the U.S.
- Asset Disposition: The company sold assets of its Vancouver facility for approximately $2.7M, retaining preferential supply rights and a contingent 10% interest in future proceeds. This eliminated a recurring cash outflow of ~$600k annually.
- Capital Strategy: The company raised approximately $841k through private placements in the first half of the fiscal year. It maintains a $12M credit facility (amended in June 2025) and is exploring non-dilutive grants.
- Digital Asset Investment: The company invested $25k in a U.S.-listed digital asset ETP as part of a treasury diversification strategy. This introduces volatility risks to earnings.
- Risks: Key risks include the failure of clinical trials, regulatory hurdles (FDA/USPTO), insufficient capital to complete development, and the volatility of digital asset investments. The company has a history of net losses and relies on future financing.
Investor Verification Checklist
- Cash Runway: Verify if the current cash balance ($1.1M) plus the $12M credit facility is sufficient to fund the completion of the Phase 2 trial and subsequent development phases without immediate dilution.
- Asset Sale Closing: Confirm the final closing status and receipt of funds for the $2.7M Vancouver facility asset sale, as the gain was recognized but closing conditions may apply.
- Revenue Sustainability: Assess the long-term viability of the Life Sciences segment revenue (white-label/wellness) given the strategic pivot to clinical-stage drug development and the reduction in manufacturing operations.
- Digital Asset Exposure: Review the specific terms of the digital asset ETP investment and the company's policy on marking-to-market, which could introduce earnings volatility.
- Stock-Based Compensation: Note the significant non-cash expense ($1.2M for six months) and the large pool of unvested options/RSUs (~$8.8M fair value) which may impact future dilution.